Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRD135S.E1 in Painful Diabetic Peripheral Neuropathy
NCT05480228Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic peripheral neuropathy (DPN) comparing NRD135S.E1 80mg/day with Matching placebo (2 arms). Primary endpoints: Superiority to placebo in relieving neuropathic pain associated with PDPN at 13 weeks and Treatment Emergent Adverse Events at 13 weeks. Started Sep 2022; status: completed.
02
Drugs
nispomeben
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT05480228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480228.